Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

Key Takeaways

• Webinar on March 31 updates BOT+BAL program.
• 1,200 patients treated with botensilimab in early trials.
• Over 900 patients evaluated balstilimab, showing favorable safety.
• Global access programs expand treatment in France and other regions.
• 2026 priorities focus on multi-tumor immunotherapy expansion.

Summary

Agenus announced a March 31, 2026 stakeholder webcast to detail progress on its botensilimab and balstilimab (BOT + BAL) immunotherapy program. The company highlighted clinical durability across multiple tumor types, with roughly 1,200 patients treated with botensilimab and over 900 with balstilimab in early‑stage trials. Executives will also discuss expanding global patient‑access pathways, including France’s AAC and Named Patient Programs. The webcast will outline Agenus’ strategic priorities for 2026 as it seeks broader adoption of its combination therapy.

Pulse Analysis

Agenus, a Lexington‑based immuno‑oncology firm, is leveraging its dual‑antibody platform to tackle cancers that have historically evaded checkpoint inhibitors. By pairing botensilimab, a CTLA‑4‑blocking antibody engineered for enhanced Fc activity, with balstilimab, a PD‑1 blocker, the company aims to convert "cold" tumors into immunologically active lesions. This strategy aligns with a broader industry shift toward combination regimens that synergize innate and adaptive immune pathways, offering a differentiated therapeutic avenue in a crowded market.

Clinical data underpinning the BOT + BAL program reflect meaningful exposure: roughly 1,200 patients have received botensilimab and more than 900 have been treated with balstilimab across Phase 1 and Phase 2 studies. Early results indicate durable responses in nine metastatic, late‑line cancers, including tumor types previously deemed immunotherapy‑resistant. The safety profile remains favorable, a critical factor for regulators and payers evaluating novel combos. These outcomes position Agenus to advance later‑stage trials and potentially secure accelerated approvals, which could accelerate revenue generation and market penetration.

Beyond data, Agenus is actively expanding patient‑access mechanisms, notably through France’s AAC and Named Patient Programs, to ensure early availability for patients lacking alternatives. The upcoming stakeholder webcast serves as a transparent forum to outline 2026 strategic priorities, from trial initiations to commercial rollout plans. By communicating progress and access initiatives, Agenus seeks to build investor confidence and solidify its role as a next‑generation immunotherapy leader, setting the stage for partnerships, licensing deals, and eventual market launch.